Table 1 Patient characteristics

From: Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

Characteristic

No. of patients

%

Age, (years)

 <5

4

14

 5–9

5

18

 10–14

12

43

 15–21

7

25

Sex

 Male

14

50

 Female

14

50

Diagnosis

 Soft tissue sarcoma (MMT 98)

5

18

 Rhabdomyosarcoma (MMT 98)

12

43

 PNET

11

39

Additional chemotherapy

 Etoposide

17

61

 Cyclophosphamide

28

100

 Thiotepa

11

39

  1. PNET, primitive neuroectodermal tumour.
  2. For patients treated on the MMT 98 study, cyclophosphamide (2 g m−2 day−1 × 3) was administered to patients on two courses of treatment, 6 and 2 weeks before receiving high-dose carboplatin, with etoposide (800 mg m−2 day−1 × 3) given 4 weeks before carboplatin. Patients treated on the PNET study received both cyclophosphamide (2 g m−2 day−1 × 2) and thiotepa (300 mg m−2 day−1) before high-dose carboplatin with time between chemotherapy treatments dependent on neutrophil and platelet count recovery.
Back to article page